CatalystFDA/Bio

GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF

GENFIT advances nangibotide into Phase 2 trial for ACLF, a key clinical catalyst.

What changed

GENFIT advances nangibotide into Phase 2 trial for ACLF, a key clinical catalyst.

Why it matters

GENFIT advances nangibotide into Phase 2 trial for ACLF, a key clinical catalyst. — impact context not separately stored; see What changed.

Sources